161 related articles for article (PubMed ID: 18259028)
1. 17Beta-estradiol increases basal but not bradykinin-stimulated release of active t-PA in young postmenopausal women.
Pretorius M; van Guilder GP; Guzman RJ; Luther JM; Brown NJ
Hypertension; 2008 Apr; 51(4):1190-6. PubMed ID: 18259028
[TBL] [Abstract][Full Text] [Related]
2. Angiotensin-converting enzyme inhibition increases basal vascular tissue plasminogen activator release in women but not in men.
Pretorius M; Luther JM; Murphey LJ; Vaughan DE; Brown NJ
Arterioscler Thromb Vasc Biol; 2005 Nov; 25(11):2435-40. PubMed ID: 16166566
[TBL] [Abstract][Full Text] [Related]
3. Bradykinin type 2 receptor BE1 genotype influences bradykinin-dependent vasodilation during angiotensin-converting enzyme inhibition.
Van Guilder GP; Pretorius M; Luther JM; Byrd JB; Hill K; Gainer JV; Brown NJ
Hypertension; 2008 Feb; 51(2):454-9. PubMed ID: 18180402
[TBL] [Abstract][Full Text] [Related]
4. Angiotensin-converting enzyme inhibition increases human vascular tissue-type plasminogen activator release through endogenous bradykinin.
Pretorius M; Rosenbaum D; Vaughan DE; Brown NJ
Circulation; 2003 Feb; 107(4):579-85. PubMed ID: 12566370
[TBL] [Abstract][Full Text] [Related]
5. Preserved tissue-type plasminogen activator release and endothelium-dependent vasodilation in postmenopausal women with NIDDM.
Manhem K; Dotevall A; Wilhelmsen L; Jern S
J Diabetes Complications; 2000; 14(3):127-34. PubMed ID: 10989320
[TBL] [Abstract][Full Text] [Related]
6. Potentiation of bradykinin-induced tissue plasminogen activator release by angiotensin-converting enzyme inhibition.
Labinjoh C; Newby DE; Pellegrini MP; Johnston NR; Boon NA; Webb DJ
J Am Coll Cardiol; 2001 Nov; 38(5):1402-8. PubMed ID: 11691515
[TBL] [Abstract][Full Text] [Related]
7. Endogenous nitric oxide contributes to bradykinin-stimulated glucose uptake but attenuates vascular tissue-type plasminogen activator release.
Pretorius M; Brown NJ
J Pharmacol Exp Ther; 2010 Jan; 332(1):291-7. PubMed ID: 19841473
[TBL] [Abstract][Full Text] [Related]
8. Neutral endopeptidase inhibition augments vascular actions of bradykinin in patients treated with angiotensin-converting enzyme inhibition.
Cruden NL; Fox KA; Ludlam CA; Johnston NR; Newby DE
Hypertension; 2004 Dec; 44(6):913-8. PubMed ID: 15492133
[TBL] [Abstract][Full Text] [Related]
9. Smoking impairs bradykinin-stimulated t-PA release.
Pretorius M; Rosenbaum DA; Lefebvre J; Vaughan DE; Brown NJ
Hypertension; 2002 Mar; 39(3):767-71. PubMed ID: 11897760
[TBL] [Abstract][Full Text] [Related]
10. Regulation of local tissue-type plasminogen activator release by endothelium-dependent and endothelium-independent agonists in human vasculature.
Stein CM; Brown N; Vaughan DE; Lang CC; Wood AJ
J Am Coll Cardiol; 1998 Jul; 32(1):117-22. PubMed ID: 9669258
[TBL] [Abstract][Full Text] [Related]
11. Bradykinin stimulates tissue plasminogen activator release from human forearm vasculature through B(2) receptor-dependent, NO synthase-independent, and cyclooxygenase-independent pathway.
Brown NJ; Gainer JV; Murphey LJ; Vaughan DE
Circulation; 2000 Oct; 102(18):2190-6. PubMed ID: 11056091
[TBL] [Abstract][Full Text] [Related]
12. Angiotensin-converting enzyme inhibition augments coronary release of tissue plasminogen activator in women but not in men.
Matsumoto T; Takashima H; Nakae I; Yamane T; Hayashi H; Horie M;
Hypertension; 2010 Sep; 56(3):364-8. PubMed ID: 20606106
[TBL] [Abstract][Full Text] [Related]
13. Acute and chronic effects of oestrogen on endothelial tissue-type plasminogen activator release in postmenopausal women.
Hoetzer GL; Stauffer BL; Irmiger HM; Ng M; Smith DT; DeSouza CA
J Physiol; 2003 Sep; 551(Pt 2):721-8. PubMed ID: 12815179
[TBL] [Abstract][Full Text] [Related]
14. Substance P increases sympathetic activity during combined angiotensin-converting enzyme and dipeptidyl peptidase-4 inhibition.
Devin JK; Pretorius M; Nian H; Yu C; Billings FT; Brown NJ
Hypertension; 2014 May; 63(5):951-7. PubMed ID: 24516103
[TBL] [Abstract][Full Text] [Related]
15. B1 kinin receptor does not contribute to vascular tone or tissue plasminogen activator release in the peripheral circulation of patients with heart failure.
Cruden NL; Tse GH; Fox KA; Ludlam CA; Megson I; Newby DE
Arterioscler Thromb Vasc Biol; 2005 Apr; 25(4):772-7. PubMed ID: 15681300
[TBL] [Abstract][Full Text] [Related]
16. Fibrinolytic actions of intra-arterial angiotensin II and bradykinin in vivo in man.
Labinjoh C; Newby DE; Dawson P; Johnston NR; Ludlam CA; Boon NA; Webb DJ
Cardiovasc Res; 2000 Sep; 47(4):707-14. PubMed ID: 10974219
[TBL] [Abstract][Full Text] [Related]
17. Endothelium-derived hyperpolarizing factor mediates bradykinin-stimulated tissue plasminogen activator release in humans.
Rahman AM; Murrow JR; Ozkor MA; Kavtaradze N; Lin J; De Staercke C; Hooper WC; Manatunga A; Hayek S; Quyyumi AA
J Vasc Res; 2014; 51(3):200-8. PubMed ID: 24925526
[TBL] [Abstract][Full Text] [Related]
18. Abnormal flow-mediated epicardial vasomotion in human coronary arteries is improved by angiotensin-converting enzyme inhibition: a potential role of bradykinin.
Prasad A; Husain S; Quyyumi AA
J Am Coll Cardiol; 1999 Mar; 33(3):796-804. PubMed ID: 10080484
[TBL] [Abstract][Full Text] [Related]
19. Does long-term angiotensin converting enzyme inhibition affect the concentration of tissue-type plasminogen activator-plasminogen activator inhibitor-1 in the blood of patients with a previous myocardial infarction.
Pedersen OD; Gram J; Jeunemaitre X; Billaud E; Jespersen J
Coron Artery Dis; 1997 May; 8(5):283-91. PubMed ID: 9285181
[TBL] [Abstract][Full Text] [Related]
20. Bradykinin stimulates tissue plasminogen activator release in human vasculature.
Brown NJ; Gainer JV; Stein CM; Vaughan DE
Hypertension; 1999 Jun; 33(6):1431-5. PubMed ID: 10373228
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
